<DOC>
	<DOCNO>NCT02017613</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy RP6530 , dual PI3K delta/gamma inhibitor patient hematologic malignancy .</brief_summary>
	<brief_title>Safety Efficacy Study Dual PI3K Delta/Gamma Inhibitor Hematological Malignancies</brief_title>
	<detailed_description>The Maximum tolerate dose ( MTD ) determine base safety , pharmacokinetic ( PK ) efficacy data . Safety analyse include AE 's , AE 's related drug , SAE 's , laboratory value , vitals/ ECG dose limit toxicity ( DLT ) . PK include measurement peak plasma concentration ( Cmax ) , area plasma concentration versus time curve ( AUC ) , time maximum concentration observe ( Tmax ) . Efficacy analyse include overall response rate ( ORR ) duration response ( DOR ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Refractory relapse least 1 prior treatment line . ECOG performance status ≤2 Patients must ≥18 year age Able give write informed consent . Any cancer therapy last 4 week limit palliative radiation &lt; 2 week Patients HBV , HCV HIV infection Autologous hematologic stem cell transplant within 3 month study entry . Allogeneic hematologic stem cell transplant within 12 month . Previous therapy GS1101 ( CAL101 , idelalisib ) , IPI145 , TGR1202 drug specifically inhibit PI3K/ mTOR ( include temsirolimus , everolimus ) , AKT BTK Inhibitor ( include Ibrutinib ) . Patients immunosuppressive therapy include systemic corticosteroid . Patients receive chronic systemic anticoagulation therapy ( warfarin sodium heparin , etc. ) . Patients known history liver disorder . Patients uncontrolled Diabetes Type I Type II Any severe and/or uncontrolled medical condition condition could affect participation study . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>CLL , SLL , NHL , SLL , PTCL , CTCL , MM , AML</keyword>
</DOC>